{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T10:21:40Z","timestamp":1648981300286},"reference-count":10,"publisher":"Societas Neurologica Japonica","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rinsho Shinkeigaku"],"published-print":{"date-parts":[[2013]]},"DOI":"10.5692\/clinicalneurol.53.1303","type":"journal-article","created":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T23:13:42Z","timestamp":1385680422000},"page":"1303-1305","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of pure ocular myasthenia: a proposal from Japan MG registry 2012"],"prefix":"10.5692","volume":"53","author":[{"given":"Shigeaki","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3663","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Evoli A, Batocchi AP, Minisci C, et al. Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord 2001;11:208-216.","DOI":"10.1016\/S0960-8966(00)00173-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141-149.","DOI":"10.1002\/mus.20950"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Bever CT, Jr., Aquino AV, Penn AS, et al. Prognosis of ocular myasthenia. Ann Neurol 1983;14:516-519.","DOI":"10.1002\/ana.410140504"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997;62:156-162.","DOI":"10.1136\/jnnp.62.2.156"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003;60:243-248.","DOI":"10.1001\/archneur.60.2.243"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Benatar M, Kaminski HJ. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007;68:2144-2149.","DOI":"10.1212\/01.wnl.0000263481.14289.90"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology 2008;71:1335-1341.","DOI":"10.1212\/01.wnl.0000327669.75695.38"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Masuda M, Utsugisawa K, Suzuki S, et al. The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve 2012;46:166-173.","DOI":"10.1002\/mus.23398"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kaminski HJ, Daroff RB. Treatment of ocular myasthenia: steroids only when compelled. Arch Neurol 2000;57:752-753.","DOI":"10.1001\/archneur.57.5.752"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Nagane Y, Utsugisawa K, Suzuki S, et al. Topical naphazoline in the treatment of myasthenic blepharoptosis. Muscle Nerve 2011;44:41-44.","DOI":"10.1002\/mus.22002"}],"container-title":["Rinsho Shinkeigaku"],"original-title":["\u773c\u7b4b\u578bMG\u6cbb\u7642\u306e\u73fe\u72b6\uff08Japan MG registry 2012\uff09\u3068\u63d0\u8a00"],"language":"en","deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T03:21:51Z","timestamp":1498101711000},"score":1,"resource":{"primary":{"URL":"http:\/\/jlc.jst.go.jp\/DN\/JST.JSTAGE\/clinicalneurol\/53.1303?lang=en&from=CrossRef&type=abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.5692\/clinicalneurol.53.1303","relation":{},"ISSN":["0009-918X","1882-0654"],"issn-type":[{"value":"0009-918X","type":"print"},{"value":"1882-0654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}